Literature DB >> 9398884

Is antrum or corpus the best site for culture of Helicobacter pylori?

M M Yousfi1, R Reddy, M S Osato, D Y Graham.   

Abstract

BACKGROUND: Isolating Helicobacter pylori on culture media and performing antibiotic susceptibility testing is potentially the most useful tool for guiding antibiotic therapy, especially when antimicrobial resistance is suspected. The aim of this study was to determine whether the yield of H. pylori culture was related to the site from which the gastric specimen was obtained either before or after therapy.
METHODS: Gastric mucosal biopsies from the antrum and the corpus of the stomach were cultured. H. pylori status was determined by histological assessment using the Genta stain.
RESULTS: Fifty-two patients with documented H. pylori infection were studied: Twenty-three were tested before antibiotic therapy and 29 after therapy had failed. In 47 patients (90%), both antral and corpus culture specimens were positive. In 5 patients (10%), only one site was positive, with three false-negative antral and two false negative corpus cultures. The overall sensitivity of culture in detecting H. pylori infection was 95% (95% confidence interval = 89-98%) and was not significantly different for the antrum or corpus, either before or after therapy.
CONCLUSION: Culture of gastric biopsies from either the antrum or the corpus has an excellent diagnostic yield even in patients who failed antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9398884     DOI: 10.1111/j.1523-5378.1996.tb00016.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  1 in total

1.  Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection.

Authors:  Michael Selgrad; Ina Tammer; Cosima Langner; Jan Bornschein; Julia Meißle; Arne Kandulski; Mariya Varbanova; Thomas Wex; Dirk Schlüter; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.